

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 17, 2026**

**NEXGEL, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-41173**

(Commission  
File Number)

**26-4042544**

(IRS Employer  
Identification No.)

**2150 Cabot Boulevard West, Suite B  
Langhorne, Pennsylvania**

(Address of principal executive offices)

**19047**

(Zip Code)

Registrant's telephone number, including area code: **(215) 702-8550**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

**Title of each class**

Common Stock, par value \$0.001  
Warrants to Purchase Common Stock

**Trading Symbol(s)**

NXGL  
NXGLW

**Name of each exchange on which registered**

The Nasdaq Capital Market LLC  
The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On June 17, 2026, NexGel, Inc. began utilizing a new investor presentation, a copy of which is attached hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	<a href="#">NexGel, Inc. Investor Presentation, dated June 2026.</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 17, 2026

**NEXGEL, INC.**

By: /s/ Adam Levy  
Adam Levy  
Chief Executive Officer

---



## BioNx Surgical Introduction

INVESTOR PRESENTATION  
JUNE 2026

(NASDAQ: NXGL)

---

## FORWARD LOOKING STATEMENTS

---

This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC.

Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Except as otherwise required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

## KEY INVESTOR HIGHLIGHTS

---

- ✓ Completed recent asset purchase transaction with Celularity.
  - ✓ Reset NexGel around highest-convection capabilities.
  - ✓ Increase focus in Medtech/Life Science mission.
- ✓ Acquired a blue-chip roster of talent across multiple functional areas and led by a renowned foot & ankle surgeon to anchor the corporate mission.
- ✓ Established the BioNx Surgical division as the engine behind NexGel's strategic vision, delivering a scalable, high-touch commercialization engine.
- ✓ Developing a strategic partnership with Fountainhead LifeSciences
  - ✓ Creating an integrated life sciences platform, with BioNx serving as the gateway to the platform.
- ✓ Intentionally expanding product lineup around innovative technologies and solutions to improve all parts of the procedural experience, while ensuring the practitioner can deliver procedural excellence.
- ✓ Solidifying growth strategy.
  - ✓ Now has a robust pipeline of R&D designed around the surgeon's real-life insight that will advance the standard of care delivered and the quality of life a patient will experience.

## REFOCUSSED, REBUILT, RE-ENERGIZED

---




### BEFORE

- Founded as high-quality hydrogel manufacturer with medical device pipeline.
- Under-utilized infrastructure
- No access to direct sales
- Created an overreliance on large partners.



### TRANSFORMATION

- **NexGel Inc.** acquired diversified portfolio of established regenerative biomaterial products and technologies from Celularity Inc., focused on tendon repair, skin grafts, and bone growth—all within the rapidly growing regenerative biomaterials market.
- Acquired experienced commercial team deployed across wound care and surgical sales channels bringing market access to over 500+ approved hospital accounts. Launched **BioNx Surgical**.
- Simultaneously, formed strategic partnership with **Fountainhead LifeSciences Inc.**, securing a \$6.5M investment, and access to a portfolio of innovation, training, manufacturing and additional commercialization.



### TODAY

- Market-facing gateway for surgeon engagement that translates clinical insight into commercial scale.
- Curator of a true closed-loop experience centered on the surgeon.
- Single access point to a full continuum of care portfolio of solutions.
- Diversified across multiple clinical verticals and reimbursement channels.

## OUR STRATEGIC PARTNER: FOUNTAINHEAD LIFESCIENCES

---

*Fountainhead is built for the surgeon and procedural specialists experience, we are aligning innovation, technology, training and education to advance procedural excellence.*

Fountainhead is the platform that powers the full ecosystem, bringing together:

- **CadaverLab SA:** serves as the structural link of the platform, the ecosystem. Is the proving ground where innovation, training and real procedural behavior converge.
- **Sequence LifeSciences:** drives biologic and allograft solutions for wound care, ocular, and other clinical applications.
- **NVISION Biomedical Technologies:** develops NGAGE-powered biointegrative implants improving foot and ankle surgical outcomes.
- **LockHill Advanced Manufacturing Technologies:** ensures scalable, high-quality manufacturing aligned with clinical and regulatory standards.
- **Aequitas Innovations:** pilots research and development with The University of Texas- San Antonio and UT Health Science Center to commercialize IP, sustaining ongoing innovation and market growth.

### **Strategic Investment:**

- \$6.5M capital investment, representing approximately 35% ownership
- 2 board seats.
- Deep manufacturing capabilities
- Expanded product access
- R&D support across shared 510(k) pipeline and future product development
- A robust quality & regulatory structure.

## FOUNTAINHEAD GROUP OF COMPANIES

---

### **N**VISION™

BIOMEDICAL TECHNOLOGIES

- Engineering Design
- Prototyping
- Intellectual Property
- FDA Regulatory
- Quality Management System
- Product Commercialization

### **L**OCKHILL ADVANCED MANUFACTURING TECHNOLOGY

- 10 - Polymer & Resin Printers
- Post Processing Milling & Machining
- FDA Regulatory Assistance
- Contract Manufacturing

### **Sequence**™ LIFE SCIENCE

- 13 ISO Class 5 Cleanrooms
- 1 ISO Class 7 Lyophilization Room
- 1 ISO Class 7 Packaging Room
- 1,000 sqft. R&D wetlab
- Regulatory Assistance
- Process Validation
- Contract Manufacturing & Packaging

### **Cadaver Lab SA**

- 2,500 sqft, 12 Station Cadaver Lab Suite & Bioskills Lab
- State of the Art Classroom/Lecture Hall with accommodations for 75
- 750 sqft Overflow area for additional training

## FOUNTAINHEAD: A QUIET GIANT IN THE PRIVATE SECTOR WITH BIONX SURGICAL

---




- 35 Cleared 510k's
    - *Average time for concept to clearance is 15 months.*
  - 21 Issued patents
  - 12 Pending Applications
  - 20 Projects in development
- BioNx steady flow of products + Fountainhead becomes BioNx R&D Partner
  - Products include:
    - *Spine*
    - *Trauma*
    - *Extremities*
    - *Joints*
    - *Sports Medicine*
    - *Soft Tissue*
    - *Wound Care*
    - *Ocular*

# A VERTICALLY INTEGRATED LIFE SCIENCES PLATFORM

## FOUNTAINHEAD

"The LifeSciences Platform"



# BIONX SURGICAL: COMMERCIALIZATION & ENGAGEMENT GATEWAY

---



## Unified Market-Facing Engagement Gateway

- BioNx is NOT just another portfolio company, it is the commercial interface of the entire platform (first interaction for surgeons and other procedural specialist to everything on the platform).
- We focus on controlling demand through clinical credibility and education-drive engagement.
- By integrating education with commercialization, we support the adoption and avoid volume focused sales pitfalls.

## Effective Execution Needs To Be Intentionally Different

1. **Commercial Engine Element--** drive sales, distributor relationships management, market access, and result accountability.
2. **Marketing Narrative Element--** surgeon engagement experience, thought leadership, branding & market positioning
3. **Integration Bridge Element--** this is the big unlock! The engine that links surgeon credibility with platform innovation — capturing insight in, delivering education and solutions out, and strengthening the partnership at every turn.

## Why would this become so valuable?

- Success means BioNx shifts from simply supplying products to shaping demand. This creates a defensible, branded experience anchored in surgeon engagement—an advantage that competitors cannot easily replicate.

## END STATE VISION AND VALUE CREATION

---

### Scaled Life Sciences Platform

- Aiming to build a large, integrated platform generating over \$250M revenue with a surgeon-centered approach.

### Value Creation Drivers

- Growth fueled by revenue increase and multiple expansion through defensibility, integration, and learning velocity.

### Controlling Value Chain

- Control over insight, validation, innovation, manufacturing, and commercialization to lead procedural categories.

### Strategic Convergence

- NexGel and Fountainhead are highly focused on unifying the platform experience, and operational processes over the next 18 months.

## GROWING THE PRODUCT PORTFOLIO

	Currently Available	Upcoming	Target Date	Reimbursement Type
Wound Care	BioVance			Private Pay
	Sentry			
		Silverseal	July 2026	
		Activate	First Quarter 2027	Medicare
		Shelter	TBD	
Surgical	Interfyl			
	BioVance 3L	Forma		
	BioVance SL	Sentinel		
Ocular		Lucent - SL	August 2026	
		Radiant - DL	August 2026	
		Vivid - 3L	August 2026	

# CONSUMER PRODUCTS DIVISION

---



(NASDAQ: NXGL)

Copyright © 2026, NexGel, INC. All Rights Reserved.

12

---

## EXPERIENCED LEADERSHIP TEAM

### NEXGEL

**Adam Levy**  
CEO, NexGel

**Dr. Steve Brigido, DPM**  
President & Clinical Architect,  
BioNx Surgical

**Ian Blackman, CPA**  
Chief Financial Officer, NexGel

**Desiree Long**  
General Manager, BioNx

**Dave Hazzard**  
VP Sales, BioNx Surgical

### FOUNTAINHEAD

**Brian Kieser, CPA**  
CEO, Fountainhead

**Kevin Harris, CFA**  
Chief Operating Officer

**Pete Martinez**  
SVP, Tissue Operations,  
Sequence LifeSciences

**Denise Alva**  
Chief Quality & Regulatory  
Officer, Fountainhead

**Lorena Kieser**  
CEO, CadaverLab SA

**Sy Griffey, PhD**  
Research & Development,  
Sequence LifeSciences

**Tom Zink**  
SVP, Product Development

## 4-STAGES OF GROWTH STRATEGY AND MILESTONES

---

### **Stage 1 — Foundation:**

Prove the closed-loop model by building one high-quality CadaverLab, seeding a core surgeon network, and establishing early evidence that surgeon insight meaningfully connects to product outcomes.

### **Stage 2 — Integration:**

Formalize the ecosystem structure across BioNx, the CadaverLab, and product partners turning parallel capabilities into a single, legible system where training, feedback, and commercialization reinforce each other.

### **Stage 3 — Expansion:**

Scale reach regionally through additional lab locations and BioNx geographic growth, anchored by repeatable training programs and a product pipeline visibly validated through the lab without outrunning clinical credibility.

### **Stage 4 — Platform Maturity:**

Establish national presence as a recognized innovation and adoption platform where surgeon networks, procedural training, and product commercialization operate as a fully integrated flywheel with a reputation the market comes to.

## INVESTMENT SUMMARY

---

- Acquired a diversified portfolio of regenerative biomaterial products from Celularity, establishing a foundation in tendon repair, skin grafts, and bone growth.
- Built BioNx Surgical as NexGel's commercial gateway — a surgeon-centric platform connecting innovation, training, and commercialization.
- Secured a strategic partnership with Fountainhead LifeSciences, including a \$6.5M investment, 2 board seats, and access to a deep R&D and manufacturing ecosystem.
  - 35 cleared 510(k)s, 21 issued patents, 20+ products in development across surgical, wound care, and ocular verticals.
- Assembled an experienced commercial team across 500+ approved hospital accounts, with a renowned foot & ankle surgeon anchoring the clinical mission.
- Established a clear 4-stage growth strategy — from proving the closed-loop model to achieving national platform maturity.

# Contact Us

## Investor Relations

KCSA Strategic Communications  
Valter Pinto, Managing Director

PH: (212) 896-1254  
NEXGEL@KCSA.com



**NEXGEL**  
advanced hydrogel solutions